Research Flow Cytometry
Tricarico, R., Madzo, J., Scher, G., Cohen, M., Jelinek, J., Maegawa, S., Nagarathinam, R., Scher, C., Chang, W.C., Nicolas, E., Slifker, M., Zhou, Y., Devarajan, K., Cai, K.Q., Kwok, T., Nakajima, P., Xu J., Mancuso, P., Doneddu., V., Bagella, L., Williams, R., Balachandran, S., Maskalenko, N., Campbell, K., Ma, X., Cañadas, I., Viana, J., Moreno, V., Valle, L., Grivennikov, S, Peshkova, I., Kurilenko, N., Mazitova, A., Koltsova, E., Lee, H., Walsh, M., Duttweiler, R., Whetstine, J.R., Yen, T.J., Issa, J.P., and Bellacosa, A. TET1 and TDG suppress inflammatory response in intestinal tumorigenesis: implications for colorectal tumors with the CpG island methylator phenotype. Gastroenterology 2023; 164:921-36.e1. PMCID: PMC10586516 Wei, W, Song, Z, Chiba, M, Wu, W, Jeong, S, Zhang, JP, Kadin, ME, Nakagawa, M, Yang, Y. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma. Leukemia 2023;37:396-407. PMCID: PMC9949602 Gray, Z.H., Chakraborty, D., Duttweiler, R.R., Alekbaeva, G.D., Murphy, S.E., Chetal, K., Ji,F., Ferman, B.I., Honer, M.A., Wang, Z., Myers, C., Sun, R., Kaniskan, H.U., Toma, M.M., Bondarenko, E.A., Santoro, J.N., Miranda, C., Dillingham, M.E., Tang, R., Gozanim, O., Jin, J., Skorski, T., Duy, C., Lee, H., Sadreyvev, R.I., Whetstine, J.R. Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. Cell 2023;186:4528-45. PMCID: PMC10591855 Zhang, Y, Truong, B, Fahl, SP, Cai, KQ, Martinez, E, Al-Saleem, ED, Gong, Y, Liebermann, DA, Soboloff, J, Dunbrack, R, Levine, RL, Fletcher, S, Kappes, D, Sykes, SM, Shapiro, P, Wiest, DL. ERK2 substrate binding domains perform opposing roles in pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm. Blood 2022;140:359–73. PMCID: PMC9335498 Zhang, T, Yin, C, Fedorov, A, Qiao, L, Bao, H-L, Beknazarov, N, Wang, S, Gautam, A, Williams, RM, Crawford, JC, Peri, S, Studitsky, V, Beg, AA, Thomas, PG, Walkley, C, Xu, Y, Poptsova, M, Herbert, A, Balachandran, S. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature 2022;606:594-602. PMCID: PMC9373927 Aghayev, T, Mazitova, AM, Fang, J, Peshkova, IO, Rausch, M, Hung, M, White, KF, Masia, R, Titerina, EK, Fatkhullina, AR, Cousineau, I, Turcotte, S, Zhigarev, D, Marchenko, A, Khozyainova, S, Makhov, P, Tan, YF, Kossenkov, A, Wiest, D, Stagg, J, Wang, XW, Campbell, KS, Trinchieri, G, Dzutsev, A, Hill, JA, Grivennikov, SI, Koltsova, EK. Interleukin-27 signaling serves as an immunological checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma. Cancer Discov 2022;12:1960-83. PMCID: PMC9357073 Francescone, R, Vendramini-Costa, DB, Franco-Barraza, J, Wagner, J, Muir, A, Lau, AN, Gabitova, L, Pazina, T, Gupta, S, Luong, T, Shah, N, Rollins, D, Malik, R, Thapa, R, Restifo, D, Zhou, Y, Cai, KQ, Hensley, HH, Tan, Y, Kruger, WD, Devarajan, K, Balachandran, S, Klein-Szanto, AJ, El-Deiry, WS, Vander Heiden, MG, Peri, S, Campbell, KS, Astsaturov, I, Cukierman, E. Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression. Cancer Discov 2021;11:446-79. PMCID: PMC7858242 Tan, Y, Sementino, E, Menges, CW, Kukuyan, A-M, Peri, S, Cheung, M, Khazak, V, Ross, E, Fox, LA, Jhanwar, SC, Ramanathan, C, Flores, RM, Balachandran, S, Testa, JR. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res 2021;27:1200-13. PMCID: PMC7887036 Basu, J, Reis BS, Peri S, Zha J, Hua X, Ge L, Ferchen K, Nicolas E, Czyzewicz P, Cai KQ, Tan Y, Fuxman Bass JI, Walhout AJM, Grimes HL, Grivennikov SI, Mucida D, Kappes DJ. Essential role of a ThPOK autoregulatory loop in the maintenance of mature CD4+ T cell identity and function. Nat Immunol 2021;22:969-82. PMCID: PMC8887595 Wang, H, Wei, W, Zhang, JP, Song, ZH, Li, Y, Xiao, W, Liu, Y, Zeng, MS, Petrus, MN, Thomas, CJ, Kadin, KE, Nakagawa, M, Waldmann, TA, and Yang, Y. A novel model of alternative NF-kB pathway activation in anaplastic large cell lymphoma. Leukemia 2021;35:1976-89. PMCID: PMC9245089
Human Immune Monitoring
MacFarlane 4th, A.W., Yeung, H.-M., Alpaugh, R.K., Dulaimi, E., Engstrom, P.F., Dasari, A., Campbell, K.S.*, and Vijayvergia, N.* (2021) Impacts of Pembrolizumab Therapy on T and NK cells in Patients with High-grade Neuroendocrine Neoplasms. Cancer Immunol. Immunother., 70:1893-1906. PMCID: 8195815. *Corresponding authors.
Barta, S.K., Zain, J., MacFarlane 4th, A.W., Smith, S.M., Ruan, J., Fung, H.C., Tan, C.R., Yang, Y., Alpaugh, R.K., Dulaimi, E., Ross, E.A., Campbell, K.S., Khan, N., Rawat, S., Fowler, N.H., Fisher, R.I., and Oki, Y. (2019) Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin. Lymphoma Myeloma Leuk., 19:356-364. PMCID: 7433797.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, MacFarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Clin Cancer Res. 2023, 29:2052-2065. PMCID: PMC10233355
Zibelman, M., MacFarlane IV, A.W., Costello, K., McGowan, T., O’Neill, J., Kokate, R., Borghaei, H., Denlinger, C.S., Dotan, E., Geynisman, D.M., Jain, A., Martin, L., Obeid, E., Sherman, J., Devarajan, K., Ruth, K., Alpaugh, R.K., Dulaimi, E., Cukierman, E., Einarson, Campbell, K.S., and Plimack, E.R. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nature Communications, 2023, Nature Commun., 14:4513. PMCID: PMC10374608.